Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1998 Sep;57(9):511–512. doi: 10.1136/ard.57.9.511

Early treatment of rheumatoid arthritis: rationale, evidence, and implications

L B A VAN DE PUTTE, A M VAN GESTEL, P L C M VAN RIEL
PMCID: PMC1752733  PMID: 9849307

Full Text

The Full Text of this article is available as a PDF (64.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borg G., Allander E., Lund B., Berg E., Brodin U., Pettersson H., Trang L. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J Rheumatol. 1988 Dec;15(12):1747–1754. [PubMed] [Google Scholar]
  2. Chan K. W., Felson D. T., Yood R. A., Walker A. M. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum. 1994 Jun;37(6):814–820. doi: 10.1002/art.1780370606. [DOI] [PubMed] [Google Scholar]
  3. Egsmose C., Lund B., Borg G., Pettersson H., Berg E., Brodin U., Trang L. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol. 1995 Dec;22(12):2208–2213. [PubMed] [Google Scholar]
  4. Harrison B. J., Symmons D. P., Brennan P., Barrett E. M., Silman A. J. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol. 1996 Nov;35(11):1096–1100. doi: 10.1093/rheumatology/35.11.1096. [DOI] [PubMed] [Google Scholar]
  5. Iannuzzi L., Dawson N., Zein N., Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med. 1983 Oct 27;309(17):1023–1028. doi: 10.1056/NEJM198310273091704. [DOI] [PubMed] [Google Scholar]
  6. Jeurissen M. E., Boerbooms A. M., van de Putte L. B., Doesburg W. H., Lemmens A. M. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med. 1991 Jun 15;114(12):999–1004. doi: 10.7326/0003-4819-114-12-999. [DOI] [PubMed] [Google Scholar]
  7. Joosten L. A., Helsen M. M., van de Loo F. A., van den Berg W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996 May;39(5):797–809. doi: 10.1002/art.1780390513. [DOI] [PubMed] [Google Scholar]
  8. Maini R. N. A perspective on anti-cytokine and anti-T cell-directed therapies in rheumatoid arthritis. Clin Exp Rheumatol. 1995 Sep-Oct;13 (Suppl 12):S35–S40. [PubMed] [Google Scholar]
  9. Mitchell D. M., Spitz P. W., Young D. Y., Bloch D. A., McShane D. J., Fries J. F. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 1986 Jun;29(6):706–714. doi: 10.1002/art.1780290602. [DOI] [PubMed] [Google Scholar]
  10. Moreland L. W., Heck L. W., Jr, Koopman W. J. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 1997 Mar;40(3):397–409. doi: 10.1002/art.1780400302. [DOI] [PubMed] [Google Scholar]
  11. Möttönen T., Paimela L., Ahonen J., Helve T., Hannonen P., Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum. 1996 Jun;39(6):996–1005. doi: 10.1002/art.1780390617. [DOI] [PubMed] [Google Scholar]
  12. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol. 1995 Nov;34 (Suppl 2):59–73. [PubMed] [Google Scholar]
  13. Strand V., Keystone E., Breedveld F. Biologic agents for the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 1996 Feb;22(1):117–132. doi: 10.1016/s0889-857x(05)70265-9. [DOI] [PubMed] [Google Scholar]
  14. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995 Nov;9(4):619–632. doi: 10.1016/s0950-3579(05)80305-x. [DOI] [PubMed] [Google Scholar]
  15. van Gestel A. M., Haagsma C. J., Furst D. E., van Riel P. L. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). Baillieres Clin Rheumatol. 1997 Feb;11(1):65–82. doi: 10.1016/s0950-3579(97)80033-7. [DOI] [PubMed] [Google Scholar]
  16. van Leeuwen M. A., van der Heijde D. M., van Rijswijk M. H., Houtman P. M., van Riel P. L., van de Putte L. B., Limburg P. C. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol. 1994 Mar;21(3):425–429. [PubMed] [Google Scholar]
  17. van der Heide A., Jacobs J. W., Bijlsma J. W., Heurkens A. H., van Booma-Frankfort C., van der Veen M. J., Haanen H. C., Hofman D. M., van Albada-Kuipers G. A., ter Borg E. J. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996 Apr 15;124(8):699–707. doi: 10.7326/0003-4819-124-8-199604150-00001. [DOI] [PubMed] [Google Scholar]
  18. van der Heijde D. M. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995 Nov;34 (Suppl 2):74–78. [PubMed] [Google Scholar]
  19. van der Heijde D. M., van 't Hof M., van Riel P. L., van de Putte L. B. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol. 1993 Mar;20(3):538–541. [PubMed] [Google Scholar]
  20. van der Heijde D. M., van Riel P. L., Nuver-Zwart I. H., van de Putte L. B. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet. 1990 Mar 3;335(8688):539–539. doi: 10.1016/0140-6736(90)90771-v. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES